AstraZeneca inks $730m licensing deal for rare heart disease treatment

Alexion, AstraZeneca’s rare disease group, has entered into an exclusive licensing agreement with Neurimmune AG for NI006, an antibody in development for the treatment of the heart condition, transthyretin amyloid cardiomyopathy (ATTR-CM).

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Generics

AstraZeneca wins patent infringement case over Farxiga generic

19 October 2021 AstraZeneca has convinced a federal court to uphold challenged claims of a patent related to its diabetes drug Farxiga.

Americas

AstraZeneca aims to stifle Mylan’s revived shot at generic inhaler

27 January 2022 AstraZeneca has urged the US Court of Appeals for the Federal Circuit to revisit a split panel decision that breathed new life into Mylan’s bid to produce a generic version of the asthma inhaler, Symbicort Turbohaler.

Generics

AstraZeneca, MSD sue MSN and Sandoz over Calquence generics

8 February 2022 AstraZeneca and Merck, Sharp & Dohme have filed a pair of lawsuits against MSN and Sandoz, claiming their planned generic versions of its leukaemia treatment Calquence infringe six patents.